AstraZeneca and Daiichi Sankyo have agreed to work with Summit Therapeutics on clinical trials combining the antibody-drug conjugate Datroway with Summit’s immunotherapy candidate ivonescimab. The companies plan to begin with a Phase 3 trial in previously untreated triple-negative breast cancer.
Datroway, or datopotamab deruxtecan, is an antibody-drug conjugate that targets TROP2, a protein expressed in several tumor types. It was discovered by Daiichi Sankyo and is jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. Ivonescimab is a bispecific antibody designed to block PD-1 and VEGF, two pathways involved in cancer growth and immune response.
The collaboration will evaluate the combination in multiple tumor types, including breast and lung cancers. AstraZeneca or Daiichi Sankyo will sponsor the planned studies. Each company will provide its own medicine, contribute to trial costs and retain development and commercial rights to its respective product.
Datroway is approved in more than 30 countries or regions for certain adults with unresectable or metastatic triple-negative breast cancer and in more than 45 markets for specified patients with hormone receptor-positive, HER2-negative breast cancer. It is also approved in the United States and several other countries for certain patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer following prior treatment.
Ivonescimab is approved in China for certain patients with non-small cell lung cancer. A U.S. biologics license application seeking approval in EGFR-mutated non-small cell lung cancer is under FDA review.
The agreement follows AstraZeneca’s separate collaboration with Summit involving sonesitatug vedotin and ivonescimab.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!